Candidate gene association studies and risk of chronic lymphocytic leukemia: A systematic review and meta-analysis

Leukemia and Lymphoma

Volumn 55, Issue 1, 2014, Pages 160-167

  Sava, Georgina P ^a   Speedy, Helen E ^a   Houlston, Richard S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Chronic lymphocytic leukemia; False positive report probability; Meta analysis; Polymorphisms; Risk

Indexed keywords

CARCINOGEN;

APOPTOSIS; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CHRONIC LYMPHATIC LEUKEMIA; DATA EXTRACTION; DNA POLYMORPHISM; DNA REPAIR; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE GENE; META ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; SAMPLE SIZE; SYSTEMATIC REVIEW;

APOPTOSIS; CARCINOGENS; DNA REPAIR; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; ODDS RATIO; POLYMORPHISM, GENETIC; RISK;

EID: 84891370034     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.800197     Document Type: Article

References (60)

1. Ries LAG, Wingo PA, Miller DS, et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 2000; 88: 2398-2424.
2. Fuller SJ, Papaemmanuil E, McKinnon L, et al. Analysis of a large multi-generational family provides insight into the genetics of chronic lymphocytic leukemia. Br J. Haematol 2008; 142: 238-245.
3. Crowther-Swanepoel D, Houlston R S. Genetic variation and risk of chronic lymphocytic leukaemia. Semin Cancer Biol 2010; 20: 363-369.
4. Vineis P, Malats N, Lang M, et a l., editors. M etabolic polymorphisms and susceptibility to cancer. Lyon: IARC; 1999.
5. Starczynski J, Pepper C, Pratt G, et al. Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic leukemia once treatment is initiated. J. Clin Oncol 2005; 23: 1514-1521.
6. Sellick GS, Rudd M, Eve P, et al. The P2X7 receptor gene A1513C polymorphism does not contribute to risk of familial or sporadic chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev 2004; 13: 1065-1067.
7. Ganster C, Neesen J, Zehetmayer S, et al. DNA repair polymorphisms associated with cytogenetic subgroups in B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer 2009; 48: 760-767.
8. Rudd MF, Sellick GS, Allinson R, et al. MTHFR polymorphisms and risk of chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev 2004; 13: 2268-2270.
9. Wang S, Cozen W, Severson R, et al. Cyclin D1 splice variant and risk for non-Hodgkin lymphoma. Hum Genet 2006; 120: 297-300.
10. Lemos MC, Cabrita FJ, Silva HA, et al. Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Carcinogenesis 1999; 20: 1225-1229.
11. Alderson P, Green S, Higgins JPT, editors. Cochrane reviewers ' handbook 4.2.2. Chichester, UK: John Wiley & Sons, Ltd.; 2004.
12. Liberati A, Altman DG, TetzlaffJ, et al. The PRISMA statement for reporting systematic reviews and meta-Analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ 2009; 339: B2700.
13. Zhuo W, Zhang L, Ling J, et al. MDM2 SNP309 variation contributes to leukemia risk: Meta-Analyses based on 7259 subjects. Leuk Lymphoma 2012; 53: 2245-2252.
14. Slager SL, Kay NE, Fredericksen ZS, et al. Susceptibility genes and B-chronic lymphocytic leukaemia. Br J. Haematol 2007; 139: 762-771.
15. Mantel N, Haenszel W. S tatistical aspects of the analysis of data from retrospective studies of disease. J. Natl Cancer Inst 1959; 22: 719-748.
16. DerSimonian R, Laird N. Meta-Analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
17. Egger M, Smith GD, Schneider M, et al. Bias in meta-Analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
18. Hardy GH. Mendelian proportions in a mixed population. Science 1908; 28: 49-50.
19. Wacholder S, Chanock S, Garcia-Closas M, et al. A ssessing the probability that a positive report is false: An approach for molecular epidemiology studies. J. Natl Cancer Inst 2004; 96: 434-442.
20. Thomas DC, Clayton DG. Betting odds and genetic associations. J. Natl Cancer Inst 2004; 96: 421-423.
21. Johnson AD, Handsaker RE, Pulit SL, et al. SNAP: A web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 2008; 24: 2938-2939.
22. Morton LM, Purdue MP, Zheng T, et al. Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development. Cancer Epidemiol Biomarkers Prev 2009; 18: 1259-1270.
23. Kilfoy BA, Zheng T, Lan Q, et al. Genetic variation in N-Acetyltransferases 1 and 2, cigarette smoking, and risk of non-Hodgkin lymphoma. Cancer Causes Control 2010; 21: 127-133.
24. Lim U, Wang SS, Hartge P, et al. Gene-nutrient interactions among determinants of folate and one-carbon metabolism on the risk of non-Hodgkin lymphoma: NCI-SEER Case-Control Study. Blood 2007; 109: 3050-3059.
25. Wang SS, Cerhan JR, Hartge P, et al. Common genetic variants in proinfl ammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res 2006; 66: 9771-9780.
26. Morton LM, Schenk M, Hein DW, et al. Genetic variation in N-Acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphoma. Pharmacogenet Genomics 2006; 16: 537-545.
27. Chiu BCH, Kolar C, Gapstur SM, et al. Association of NAT and GST polymorphisms with non-Hodgkin's lymphoma: A population-based case-control study. Br J. Haematol 2005; 128: 610-615.
28. Wang SS, Menashe I, Cerhan JR, et al. Variations in chromosomes 9 and 6p21.3 with risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2011; 20: 42-49.
29. Ennas MG, Moore PS, Zucca M, et al. Interleukin-1B (IL1B) and interleukin-6 (IL6) gene polymorphisms are associated with risk of chronic lymphocytic leukaemia. Hematol Oncol 2008; 26: 98-103.
30. Demeter J, Porzsolt F, Räm isch S, et al. Polymorphism of the tumour necrosis factor-Alpha and lymphotoxin-Alpha genes in chronic lymphocytic leukaemia. Br J. Haematol 1997; 97: 107-112.
31. Wihlborg C, Sjöberg J, Intaglietta M, et al. Tumour necrosis factor-〈 cytokine promoter gene polymorphism in Hodgkin's disease and chronic lymphocytic leukaemia. Br J. Haematol 1999; 104: 346-349.
32. Wang SS, Purdue MP, Cerhan JR, et al. Common gene variants in the tumor necrosis factor (TNF) and TNF receptor superfamilies and NF-kB transcription factors and non-Hodgkin lymphoma risk. PLoS One 2009; 4: E5360.
33. Cerhan JR, Liu-Mares W, Fredericksen ZS, et al. Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 2008; 17: 3161-3169.
34. Bogunia-Kubik K, Mazur G, Urbanowicz I, et al. Lack of association between the TNF-Alpha promoter gene polymorphism and susceptibility to B-cell chronic lymphocytic leukaemia. Int J. Immunogenet 2006; 33: 21-24.
35. Nieters A, Beckmann L, Deeg E, et al. Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun 2006; 7: 615-624.
36. Guzowski DA, Chandrasekaran CG, Jacqueline Palma J, et al. Analysis of single nucleotide polymorphisms in the promoter region of interleukin-10 by denaturing high-performance liquid chromatography. J. Biomol Tech 2005; 16: 154-166.
37. Bassig BA, Zheng T, Zhang Y, et al. Polymorphisms in complement system genes and risk of non-Hodgkin lymphoma. Environ Mol Mutagen 2012; 53: 145-151.
38. Butterbach K, Beckmann L, d e Sanjose S, et al. A ssociation of JAKSTAT pathway related genes with lymphoma risk: Results of a European case-control study (EpiLymph). Br J. Haematol 2011; 153: 318-333.
39. Yuille M, Condie A, Hudson C, et al. Relationship between glutathione S-Transferase M1, T1, and P1 polymorphisms and chronic lymphocytic leukemia. Blood 2002; 99: 4216-4218.
40. Jamroziak K, Balcerczak E, Smolewski P, et al. MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemia. Pharmacol Rep 2006; 58: 720-728.
41. Penna G, Allegra A, Alonci A, et al. MDR-1 polymorphisms (G2677T and C3435T) in B-chronic lymphocytic leukemia: An impact on susceptibility and prognosis. Med Oncol 2011; 28: 1549-1554.
42. Starczynski J, Pepper C, Pratt G, et al. The P2X7 receptor gene polymorphism 1513 A-C has no effect on clinical prognostic markers, in vitro sensitivity to fludarabine, Bcl-2 family protein expression or survival in B-cell chronic lymphocytic leukaemia. Br J. Haematol 2003; 123: 66-71.
43. Wiley JS, Dao-Ung LP, Gu BJ, et al. A loss-of-function polymorphic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: A molecular study. Lancet 2002; 359: 1114-1119.
44. Zhang LY, Ibbotson RE, Orchard JA, et al. P2X7 polymorphism and chronic lymphocytic leukaemia: Lack of correlation with incidence, survival and abnormalities of chromosome 12. Leukemia 2003; 17: 2097-2100.
45. Cabrini G, Falzoni S, Forchap S L,et al. A His-155 to Tyr polymorphism confers gain-of-function to the human P2X7 receptor of human leukemic lymphocytes. J. Immunol 2005; 175: 82-89.
46. Nückel H, Frey UH, Dürig J, et al. 1513A/C polymorphism in the P2X7 receptor gene in chronic lymphocytic leukemia: Absence of correlation with clinical outcome. Eur J. Haematol 2004; 72: 259-263.
47. Duman N, Aktan M, Ozturk S, et al. Investigation of Arg399Gln and Arg194Trp polymorphisms of the XRCC1 (x-ray cross-complementing group 1) gene and its correlation to sister chromatid exchange frequency in patients with chronic lymphocytic leukemia. Genet Test Mol Biomarkers 2012; 16: 287-291.
48. Nuckel H, Frey UH, Durig J, et al. Methylenetetrahydrofolate reductase (MTHFR) gene 677C-T and 1298A-C polymorphisms are associated with differential apoptosis of leukemic B cells in vitro and disease progression in chronic lymphocytic leukemia. Leukemia 2004; 18: 1816-1823.
49. Hussain SR, Naqvi H, Raza ST, et al. Methylenetetrahydrofolate reductase C677T genetic polymorphisms and risk of leukaemia among the North Indian population. Cancer Epidemiol 2012; 36: E227-e231.
50. Fernberg P, Chang ET, Duvefelt K, et al. Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma. Cancer Causes Control 2010; 21: 759-769.
51. Jamroziak K, Szemraj Z, Grzybowska-Izydorczyk O, et al. CD38 gene polymorphisms contribute to genetic susceptibility to B-cell chronic lymphocytic leukemia: Evidence from two case-control studies in Polish Caucasians. Cancer Epidemiol Biomarkers Prev 2009; 18: 945-953.
52. Abramenko IV, Bilous NI, Pleskach GV, et al. CD38 gene polymorphism and risk of chronic lymphocytic leukemia. Leuk Res 2012; 36: 1237-1240.
53. HindorffLA, Sethupathy P, Junkins HA, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci 2009; 106: 9362-9367.
54. Horner MJ, Ries L AG, Krapcho M, et a l., editors. S EER Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute; 2009.
55. Cardon LR, Palmer LJ. Population stratification and spurious allelic association. Lancet 2003; 361: 598-604.
56. Pritchard JK, Rosenberg NA. Use of unlinked genetic markers to detect population stratification in association studies. Am J. Hum Genet 1999; 65: 220-228.
57. Egger M, Zellweger-Zahner T, Schneider M, et al. Language bias in randomised controlled trials published in English and German. Lancet 1997; 350: 326-329.
58. Crowther-Swanepoel D, Broderick P, Di Bernardo MC, et al. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat Genet 2010; 42: 132-136.
59. Di Bernardo MC, Crowther-Swanepoel D, Broderick P, et al. A genome-wide association study identifi es six susceptibility loci for chronic lymphocytic leukemia. Nat Genet 2008; 40: 1204-1210.
60. Slager SL, Skibola CF, D i Bernardo MC, et al. Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. Blood 2012; 120: 843-846.